Arrowpoint Investment Partners’s Fractyl Health GUTS Stock Holding History

Arrowpoint Investment Partners’s Portfolio GUTS Stock Details GUTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35,000	Closed	-$55.6K	–	152
2025 Q3	$55.6K	Buy	+35,000	New	+$45.4K	0.06%	74

Other funds holding GUTS

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

HCC Manager Chicago, Illinois $10.3M AUM 6.8% 1-Year Est. Return

Arrowpoint Investment Partners's GUTS Position: Q4 2025 in Review

Arrowpoint Investment Partners sold out of Fractyl Health (GUTS) in Q4 2025, closing a stake of 35,000 shares — an estimated $55.6K sold.

Arrowpoint Investment Partners first reported a position in GUTS in Q3 2025 and held it in 1 quarter. The position peaked at $55.6K in Q3 2025. 97 funds tracked by Wall St. Rank hold GUTS as of Q4 2025.

Arrowpoint Investment Partners reported no remaining Fractyl Health position as of Q4 2025 after selling out during the quarter.
Arrowpoint Investment Partners sold 35,000 Fractyl Health shares in Q4 2025, an estimated $55.6K.
Arrowpoint Investment Partners first reported a position in Fractyl Health in Q3 2025 and held it in 1 quarter.
Arrowpoint Investment Partners's Fractyl Health position peaked at $55.6K in Q3 2025.
97 funds tracked by Wall St. Rank held Fractyl Health as of Q4 2025.

Based on Arrowpoint Investment Partners's 13F filing for Q4 2025, filed 11 Feb 2026.